How do sympathomimetics and protease inhibitors (PIs) interact?

1. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. January 12, 2019. [Full Text].

2. Nachega JB, Hsu AJ, Uthman OA, Spinewine A, Pham PA. Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. AIDS. 2012 Jul 31. 26 Suppl 1:S39-53. [Medline].

3. Liedtke MD, Vanguri A, Rathbun RC. A probable interaction between warfarin and the antiretroviral TRIO study regimen. Ann Pharmacother. 2012 Nov. 46(11):e34. [Medline].

4. Anderson AM, Chane T, Patel M, Chen S, Xue W, Easley KA. Warfarin therapy in the HIV medical home model: low rates of therapeutic anticoagulation despite adherence and differences in dosing based on specific antiretrovirals. AIDS Patient Care STDS. 2012 Aug. 26(8):454-62. [Medline]. [Full Text].

5. Siccardi M, Marzolini C, Seden K, Almond L, Kirov A, Khoo S, et al. Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. Clin Pharmacokinet. 2013 Jul. 52(7):583-92. [Medline].

6. Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, Unadkat JD. Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion. Drug Metab Dispos. 2012 Mar. 40(3):610-6. [Medline]. [Full Text].

7. Yakiwchuk EM, Foisy MM, Hughes CA. Complexity of interactions between voriconazole and antiretroviral agents. Ann Pharmacother. 2008 May. 42(5):698-703. [Medline].

8. Hughes CA, Foisy M, Tseng A. Interactions between antifungal and antiretroviral agents. Expert Opin Drug Saf. 2010 Sep. 9(5):723-42. [Medline].

9. [Guideline] Birbeck GL, French JA, Perucca E, Simpson DM, Fraimow H, George JM, et al. Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy. Neurology. 2012 Jan 10. 78(2):139-45. [Medline]. [Full Text].

10. Okulicz JF, Grandits GA, French JA, George JM, Simpson DM, Birbeck GL, et al. Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study. AIDS Res Ther. 2011 May 16. 8:18. [Medline]. [Full Text].

11. Okulicz JF, Grandits GA, French JA, Perucca E, George JM, Landrum ML, et al. The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: a case-control study. Epilepsy Res. 2013 Feb. 103(2-3):245-53. [Medline]. [Full Text].

12. Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug-Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors. Clin Pharmacokinet. 2013 Oct. 52(10):815-31. [Medline].

13. Soriano V, Vispo E, Fernandez-Montero JV, Labarga P, Barreiro P. Update on HIV/HCV coinfection. Curr HIV/AIDS Rep. 2013 Sep. 10(3):226-34. [Medline].

14. van Heeswijk RP, Beumont M, Kauffman RS, Garg V. Review of drug interactions with telaprevir and antiretrovirals. Antivir Ther. 2013. 18(4):553-60. [Medline].

15. Frassetto L, Floren L, Barin B, Browne M, Wolfe A, Roland M, et al. Changes in clearance, volume and bioavailability of immunuosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. Biopharm Drug Dispos. 2013 Aug 26. [Medline].

16. Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol. 2012 Mar-Apr. 11(2):179-85. [Medline].

17. Saberi P, Phengrasamy T, Nguyen D. Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management. HIV Med. 2013 Oct. 14(9):519-29. [Medline]. [Full Text].

Jason F Okulicz, MD, FACP, FIDSA Director, HIV Medical Evaluation Unit, Infectious Disease Service, San Antonio Military Medical Center; Associate Professor of Medicine, F Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences; Clinical Associate Professor of Medicine, University of Texas Health Science Center at San Antonio; Adjunct Clinical Instructor, Feik School of Pharmacy, University of the Incarnate Word

Jason F Okulicz, MD, FACP, FIDSA is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, Infectious Diseases Society of America

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Gilead Sciences.

Jasmeet Anand, PharmD, RPh Adjunct Instructor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Michelle R Salvaggio, MD, FACP Assistant Professor, Department of Internal Medicine, Section of Infectious Diseases, University of Oklahoma College of Medicine; Medical Director of Infectious Diseases Institute, Director, Clinical Trials Unit, Director, Ryan White Programs, Department of Medicine, University of Oklahoma Health Sciences Center; Attending Physician, Infectious Diseases Consultation Service, Infectious Diseases Institute, OU Medical Center

Michelle R Salvaggio, MD, FACP is a member of the following medical societies: American College of Physicians, Infectious Diseases Society of America

Disclosure: Received honoraria from Merck for speaking and teaching.